Menu
Search
|

Menu

Close
X

Aquinox Pharmaceuticals Inc AQXP.OQ (NASDAQ Stock Exchange Global Market)

3.01 USD
-0.16 (-5.05%)
As of 1:30 AM IST
chart
Previous Close 3.17
Open 3.20
Volume 405,073
3m Avg Volume 121,357
Today’s High 3.43
Today’s Low 2.94
52 Week High 16.85
52 Week Low 1.98
Shares Outstanding (mil) 23.46
Market Capitalization (mil) 332.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.623
FY17
-2.238
FY16
-1.963
FY15
-1.795
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
2.67
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-38.16
14.61
Return on Equity (TTM)
vs sector
-38.28
16.34

EXECUTIVE LEADERSHIP

David Main
Co-Founder, President and Chief Executive Officer and Chairman of the Board, Since 2014
Salary: $365,027.00
Bonus: --
Kamran Alam
Chief Financial Officer, Vice President - Finance, Since 2011
Salary: $181,080.00
Bonus: --
Lloyd Mackenzie
Chief Operating Officer, Vice President - R&D Operations, Since 2017
Salary: --
Bonus: --
David Mitchell
Vice President - Global Regulatory Affairs & Quality Assurance, Since 2014
Salary: --
Bonus: --
Barbara Troupin
Chief Medical Officer, Vice President - Clinical Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

887 Great Northern Way Suite 450
VANCOUVER   BC   V5T 4T5

Phone: +1604.6299223

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.

SPONSORED STORIES